Sabarinath V. Radhakrishnan

Abstract Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in cancer treatment. Nevertheless, most patients receiving CAR T cells relapse within 5 years of treatment. CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism in which cell surface proteins transfer from tumor cells to CAR T cells.

To the editor, A quadruple induction regimen based on an anti-CD38 monoclonal antibody (CD38 quads) is the current standard of care for all newly diagnosed multiple myeloma (MM) patients, except possibly for older, frail adults [1-4]. The idea of induction therapy in MM, similar to the approach in St. Jude protocols for pediatric leukemia, is to lower tumor burden and attain deep disease control prior to autologous stem cell transplant (ASCT) [5].

Abstract Multiple myeloma (MM) is a plasma cell malignancy and most patients eventually succumb to the disease. Chimeric antigen receptor (CAR) T cells targeting B-Cell Maturation Antigen (BCMA) on MM cells have shown high-response rates, but limited durability. CD229/LY9 is a cell surface receptor present on B and T lymphocytes that is universally and strongly expressed on MM plasma cells.